15 transcripts
CHRS
Earnings call transcript
NASDAQ
2023 Q4
13 Mar 24
, to extend the lives of cancer patients. Today, we are delivering on this strategy in every front, positioning Coherus for long-term sustainable growth
INO
Earnings call transcript
NASDAQ
2023 Q4
6 Mar 24
with Coherus BioSciences to develop INO-3112 in combination with LOQTORZI for throat cancer. We also shared encouraging results for INO-4201 as an Ebola
VRCA
Earnings call transcript
NASDAQ
2023 Q4
29 Feb 24
targeted delivery to stimulate the patient's immune system and destroy cancer cells. We remain excited about the opportunity for this asset, which we
PSNL
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
leveraging our core ImmunoID NeXT platform to support biopharma customers in their drug discovery efforts in personalized cancer vaccine companies
DCGO
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
compliance rates materially. We are now offering over 30 different care gap closure services, including color cancer screenings and diabetic retinal
pd
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
of death. It's the leading cause of community-acquired pneumonia. We look at the world very practically, Gary. We look at this as there are vaccines
6cah
Earnings call transcript
NASDAQ
2023 Q4
27 Feb 24
. Specifically, last March, we announced an exclusive worldwide license and collaboration agreement with Merck to develop ModeX's nanoparticle vaccine
8j2
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
ring chart and for multiple applications, including cancer vaccines, infectious disease vaccines and cell therapies that use mRNA. This reflects
5cwv
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
be a springboard for other indications, including our preclinical therapeutic vaccine for control of pre-cancerous lesions and HPV cancers.
Switching
8d
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
revenue from Gavi.
In the U.S., the vaccination rate was down year-over-year. We were pleased that our U.S. commercial team drove an increase in our
6f5
Earnings call transcript
NYSE
2023 Q4
14 Feb 24
for vaccines and other biological countermeasures against emerging infectious diseases in underdeveloped countries.
Turning to TAS. The commercial side
nq8
Earnings call transcript
NYSE
2023 Q4
1 Feb 24
we've made to develop and deliver transformative therapies and vaccines that will help save and improve lives around the world. We reached more than
tc
Earnings call transcript
NYSE
2024 Q2
1 Feb 24
in overall pharmaceutical demand. Our Specialty Distribution business also continued to see strong demand, including with COVID-19 vaccines in the first
q1br
Earnings call transcript
NYSE
2023 Q4
31 Jan 24
and biotech. As expected, growth declined in the high single digits for the quarter and approximately 1% for the full year. In 2023, vaccine and therapy
4yne
Earnings call transcript
NYSE
2023 Q4
30 Jan 24
, and our team is driving confidently as we start 2024. From the advent of penicillin to the development of the COVID-19 vaccine, Pfizer has been
- Prev
- 1
- Next